by Alex Kadhim
Researchers at the University of Geneva have found that engineering CAR T cells to target Tenascin-C (TNC), an extracellular matrix protein enriched in glioblastoma, can shrink tumors and prolong...
by Alex Kadhim
The 2025 Tandem Meetings of ASTCT and CIBMTR showcased a rapidly evolving landscape in cellular therapy, with CAR T-cell therapy for multiple myeloma (MM) continuing to expand in both scientific...
by ASTCT
The following infographics are based on the Best of CAR T at the 2025 Tandem Meetings webinar, which aired on Sept. 16, 2025, and highlighted a comprehensive overview of the latest advancements...
by Alex Kadhim
Researchers from Massachusetts General Hospital, the Krantz Family Center for Cancer Research, and Harvard Medical School have demonstrated that a tandem CAR-T cell targeting mesothelin and MUC16...
by Alex Kadhim
n a collaborative effort, researchers from the University of Oxford, Imperial College London, and Great Ormond Street Hospital have found that bi-specific CD19–CD133 CAR-invariant NKT cells...
by Alex Kadhim
Researchers at University College London and collaborators have determined that matched allogeneic donor CD19 CAR T-cell therapy, delivered as a CAR-modified donor lymphocyte infusion, is safe and...